Rice Hall James & Associates LLC Makes New $1.46 Million Investment in Xeris Biopharma Holdings, Inc. $XERS

Rice Hall James & Associates LLC bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 1st quarter, Holdings Channel reports. The institutional investor bought 251,066 shares of the company’s stock, valued at approximately $1,456,000.

Other hedge funds have also recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new stake in shares of Xeris Biopharma during the fourth quarter worth about $25,000. KBC Group NV acquired a new position in shares of Xeris Biopharma in the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd raised its holdings in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after buying an additional 7,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after buying an additional 1,820 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after buying an additional 5,000 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $8.32 on Monday. The business has a 50 day simple moving average of $7.30 and a 200 day simple moving average of $6.76. Xeris Biopharma Holdings, Inc. has a one year low of $4.87 and a one year high of $10.08. The stock has a market capitalization of $1.44 billion, a P/E ratio of 138.67 and a beta of 0.62. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The company had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Insider Activity at Xeris Biopharma

In related news, Director Dawn Halkuff sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $121,800.00. Following the transaction, the director directly owned 95,000 shares of the company’s stock, valued at approximately $578,550. This represents a 17.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $97,440.00. Following the transaction, the director directly owned 126,500 shares in the company, valued at approximately $770,385. This trade represents a 11.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 251,500 shares of company stock worth $1,846,457. 4.35% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.